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Abstract: Peripheral arterial disease (PAD) is a major health problem affecting millions 
of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to 
marked impairment of quality of life (QoL). Besides surgical and endovascular interventions 
to improve limb-speciﬁ  c outcomes, pharmacotherapy is an effective tool in the treatment of IC. 
Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has 
demonstrated consistent efﬁ  cacy in improving exercise capacity and overall health-related 
QoL. This manuscript will review the pharmacokinetics, safety, and efﬁ  cacy of cilostazol in 
the treatment of patients with IC as well as compare this agent with other proven non-invasive 
therapies for PAD.
Keywords: peripheral arterial disease, cilostazol, intermittent claudication, supervised exercise 
therapy
Introduction
Peripheral arterial disease (PAD) is most commonly due to atherosclerosis, affects 
millions of patients worldwide, and is associated with signiﬁ  cant morbidity and 
mortality (Hiatt 2001). PAD is deﬁ  ned as an obstruction of the infra-renal abdominal 
aorta and lower extremity arteries that reduces arterial ﬂ  ow during exercise and/or 
at rest. Intermittent claudication (IC) is the most common symptom in patients with 
PAD and is associated with exercise-induced discomfort in the muscles, relieved with 
rest; this may lead to marked impairment of quality of life (QoL) and daily activities. 
However, IC is one symptom. Many patients have limited walking distance (atypical 
claudication) but do deny IC, ie, fatigue or tired or aching legs. Investigators have found 
that peak walking distance, peak walking time, and peak heart rate are all signiﬁ  cantly 
reduced in PAD patients versus healthy controls (Hiatt et al 1992).
Following the general principle that more intense activities require greater oxygen 
consumption, the requirement for oxygen consumption in a healthy person increases from 
4 mL/kg/min at rest to approximately 7 mL/kg/min for self-care, 9 mL/kg/min for house-
cleaning, 13 mL/kg/min for dancing, 14 mL/kg/min for golf, 24 mL/kg/min for jogging, 
and 31 mL/kg/min for marathon running (Ainsworth et al 2000). Considering that the 
peak oxygen capacity for an individual with PAD rarely exceeds 14.8 ± 0.8 mL/kg/min 
(Hiatt et al 1992), it appears that even when working at maximum capacity, many PAD 
patients may lack the ability to complete the activities of daily life. Subjects with IC 
exhibited a mean exercise duration of 10.6 minutes, which was approximately half 
that demonstrated by age-matched controls (p  0.05) (Hiatt et al 1987). In addition, 
the PAD-associated deﬁ  cits in exercise performance were accompanied by a roughly 
50% decline in oxygen capacity, indicating that the level of impairment in PAD is 
comparable to that associated with class III congestive heart failure (Hiatt 2001).
A number of drugs (Table 1) have been tested for IC therapy, with mostly 
disappointing results. Among the multitude of failed pharmacotherapies, prostaglandins Vascular Health and Risk Management 2008:4(6) 1198
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appeared to have promising potential more than a decade 
ago but more recently have been shown to have only modest 
efﬁ  cacy (Hiatt 2001). Antiplatelet medications, serotonin 
blockers, and vasodilators have also been studied, but thus far 
none have demonstrated signiﬁ  cant beneﬁ  ts for patients with 
IC (Hiatt 2002). In the US, two agents have been approved 
for such an indication (cilostazol and pentoxifylline), but 
only cilostazol has demonstrated consistent efﬁ  cacy in both 
extending exercise capacity and improving QoL (Beebe et al 
1999; Dawson et al 2000; Money et al 1998). As a result, 
cilostazol may be the most clinically effective pharmacologic 
option for IC in US patients. This manuscript will provide 
an overview of the pharmacology, metabolism, safety, and 
efﬁ  cacy of cilostazol in the treatment of patients with typical 
IC and will compare this agent to other proven, non-invasive 
therapies for PAD.
Pharmacology
Cilostazol (Figure 1) was approved by the Federal Drug 
Administration (FDA) in 1999 for the treatment of IC (Kumar 
and Bhattacharya 2007). It became available in generic form 
in 2006. It is a reversible selective inhibitor of phosphodies-
terase (PDE) type III. Similar to other members of its class, 
one of the primary effects of cilostazol is an increase in cyclic 
adenosine monophosphate (cAMP) in platelets, vascular 
smooth muscle, endothelial cells, and other PDE-III-rich 
cells, which may lead to a number of beneﬁ  cial outcomes 
(Table 2). Among these potential beneﬁ  ts, cilostazol has 
been shown to inhibit platelet activation/aggregation, reduce 
thrombosis, enhance vasodilation (Chapman and Goa 2003), 
and induce nitric oxide (NO) production (Hashimoto et al 
2006) as well as inhibit smooth muscle cell proliferation 
(Takahashi et al 1992; Hayashi et al 2000), increase limb 
blood ﬂ  ow (Elam et al 1998), increase plasma high-density 
lipoprotein-cholesterol (HDL-C) (Lee et al 2001) and reduce 
plasma triglyceride levels (Elam et al 1998), potentiate angio-
genesis (Lee et al 2001), and reduce inﬂ  ammation (Agrawal 
et al 2007). Although the exact mechanism for cilostazol’s 
beneﬁ  ts in IC remains unknown, any of these properties could 
potentially contribute to the symptomatic efﬁ  cacy associated 
with this pharmacologic agent.
In vitro and/or ex vivo studies using platelets from healthy 
volunteers, in patients with atherosclerosis and in patients 
with cerebrovascular disease, have shown that cilostazol 
reversibly inhibits the primary and secondary stages of 
platelet aggregation (Chapman and Goa 2003). Cilostazol 
has also been found to be superior to aspirin in suppressing 
platelet aggregation ex vivo and to have some effects on 
platelet function more potent than the antiplatelet drug 
ticlopidine (Ikeda et al 1987). Cilostazol has been shown 
to reduce platelet aggregation without prolonging bleeding 
time (Tamai et al 1999). While selectively inhibiting the 
function of human platelets, cilostazol does not affect the 
production of prostacyclin and does not inhibit the function 
of vascular endothelial cells (Tani et al 1992). Cilostazol 
also produces vasodilatation by inhibiting smooth muscle 
cell contraction secondary to the elevation of cAMP levels 
and the blocking of calcium ion release (Chapman and Goa 
2003). Cilostazol has also been shown to induce NO produc-
tion by activating endothelial nitric oxide synthase (eNOS) 
(Hashimoto et al 2006).
Cilostazol has been shown to inhibit neointimal 
hyperplasia and restore endothelial function after balloon 
injury to the carotid artery of rats by inhibiting vascular 
smooth muscle cell growth, thus stimulating the production of 
hepatocyte growth factor in rapidly regenerating endothelial 
cells (Aoki et al 2001).
Table 1 Pharmacotherapies tested for intermittent claudication 
therapy
•  Prostaglandin analogs
•  Antiplatelets
•  Serotonin blockers
•  Vasodilators
•  Naftidrofuryl
•  L-Arginine
•  Levocarnitine and propionyl levocarnitine
•  Immunomodulation therapy
•  Antimicrobial therapy
•  Phosphodiesterase inhibitors
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Cilostazol also has beneﬁ  cial effects on lipids. After 
12 weeks of therapy with cilostazol, a 10% increase in 
HDL-C and a 15% decrease in plasma triglycerides have 
been noted (Elam et al 1998; Lee et al 2001). These beneﬁ  cial 
changes with cilostazol were evident at 2 weeks for HDL-C and 
4 weeks for triglycerides and persisted throughout the 12 weeks 
of therapy. There were no signiﬁ  cant effects on low-density 
lipoprotein-cholesterol (LDL-C) or total cholesterol, but there 
was an increase of 6% in apolipoprotein A levels (Elam et al 
1998, Lee et al 2001). More interestingly, in animal models 
of myocardial infarction (MI), cilostazol in combination with 
the potent statin atorvastatin had synergistic effects on nitric 
oxide production and reduction of MI size (Manickavasagam 
et al 2007). Cilostazol may potentiate angiogenesis and has 
been shown to increase vascular endothelial growth factors 
levels, which were signiﬁ  cantly related to improved levels of 
exercise tolerance (Lee et al 2001).
Additionally, in hypertensive patients with type 2 diabetes 
mellitus, inﬂ  ammatory markers – such as highly-sensitive C 
reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), 
total leukocyte count, and plasma malondialdehyde – have been 
shown to be elevated, suggesting high levels of inﬂ  ammation 
and oxidative stress. Cilostazol has been shown to reduce these 
inﬂ  ammatory markers (Agrawal et al 2007). In a randomized, 
open, add-on preventive controlled trial speciﬁ  cally assessing 
the effects of cilostazol on inﬂ  ammatory markers, 60 hyper-
tensive patients 45 years of age with diabetes mellitus were 
recruited. Cilostazol 100 mg 2×/day was given to 30 patients 
in addition to their standard medical treatment. At the 1-month 
follow-up, the cilostazol group showed signiﬁ  cant (p  0.001) 
reductions in hs-CRP (24%), ESR (39%), total leukocyte count 
(13%), and plasma malondialdehyde (18%).
Metabolism
Cilostazol is taken orally, and maximal plasma concentration 
of the drug is observed at 2.7 hours after the final 
administration, reaching its steady state within 96 hours 
(Bramer et al 1999). Cilostazol is highly bound to plasma 
proteins, primarily albumin, and has a free fraction of up to 
5% in patients with IC (Bramer et al 1999). It is metabo-
lized by the hepatic enzyme CYP3A4 and to a lesser extent 
CYP2C19, primarily by oxidative metabolism to numerous 
metabolites (Bramer et al 1997). The main metabolites identi-
ﬁ  ed include dehydro-cilostazol and monohydroxy-cilostazol, 
which have inhibitory effects on platelet aggregation (Bramer 
et al 1997).
Safety
A black box warning indicates that cilostazol should be avoided 
in patients with congestive heart failure. The warning does 
not specify the heart failure classiﬁ  cation or the degree of 
severity that should be avoided. This warning was imposed by 
the FDA because of the prior experience of chronic oral milri-
none therapy (another PDE-III inhibitor) in patients with heart 
failure (Packer et al 1991). Regarding cardiovascular events and 
mortality, the risks associated with cilostazol seem to be numeri-
cally comparable to placebo. In an analysis that included the 
entire cilostazol safety database in addition to 4 trials conducted 
outside the US (Pratt 2001), no signiﬁ  cant differences were 
found between cilostazol- and placebo-treated groups in 
rates of MI, stroke, or cardiovascular death during follow-up 
(Pratt 2001). Moreover, in two trials the distribution of total 
cardiovascular morbidity and mortality was actually higher in 
the placebo group (8%) than among patients receiving either 
50 mg 2×/day (6%) or 100 mg 2×/day (7%) doses of cilostazol 
(Pratt 2001). Thus, cilostazol seems to be a relatively safe 
alternative for IC therapy, offering an acceptable risk-beneﬁ  t 
proﬁ  le for patients with this condition. However, because of the 
existing black box warning against giving cilostazol to patients 
with congestive heart failure, the authors do not recommend 
prescribing cilostazol to such patients with IC.
Similar to other drugs in its class, cilostazol is associated 
with a fairly high frequency of non-life threatening adverse 
effects, particularly headaches, which may occur as a result 
of its vasodilatory properties. Headaches occurred in 443 of 
1374 patients (32%) treated with cilostazol compared with 
40 of 355 (11%) treated with the other approved therapy 
for IC, pentoxifylline, and 127 of 973 (13%) treated with 
placebo (Pratt 2001). In addition, more patients in the 
cilostazol group than in the pentoxifylline and placebo groups 
reported diarrhea (17% versus 8% and 7%, respectively), 
abnormal stools (14% versus 5% and 4%, respectively), 
peripheral edema (7% versus 4% and 4%, respectively), and 
palpitations (9% versus 2% and 1%, respectively).
Table 2 Beneﬁ  cial effects of cilostazol
•  Inhibits platelet activation and aggregation
•  Reduces thrombosis
•  Inhibits smooth muscle cell contraction
•  Inhibits smooth muscle cell proliferation
•  Increases limb blood ﬂ  ow
•  Increases plasma high density lipoprotein-cholesterol levels
•  Reduces plasma triglyceride levels
•  Potentiates angiogenesis
•  Reduces inﬂ  ammationVascular Health and Risk Management 2008:4(6) 1200
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A large (n = 1439) ongoing, long-term, post-marketing 
clinical study conducted in the US, Japan and other Asian 
countries, South America, and the UK from 1999 through 
2003 recently concluded (Hiatt 2006). Patients exposed 
to marketed formulations of cilostazol were evaluated to 
measure spontaneously reported adverse events. At the end 
of the study, 872 treatment-emergent adverse events were 
reported. A total of 773 events were considered serious 
and 99 non-serious according to FDA deﬁ  nitions. Of these, 
61 events in 41 cases were considered drug related by the 
study investigators. Treatment-related serious adverse events 
occurring with the greatest frequency included congestive 
heart failure (14 cases; 2%), gastrointestinal hemorrhage 
(6 cases; 1%), atrial ﬁ  brillation (4 cases; 1%), diarrhea 
(3 cases; 1%), and dyspnea (3 cases; 1%). At total of 
572 events were considered unexpected. Of the 872 serious 
and non-serious events observed, 181 required the discontin-
uation of cilostazol due to adverse events. The most frequent 
adverse events requiring discontinuation were congestive 
heart failure (26 cases; 2%), diarrhea (15 cases; 1%), and 
headaches (14 cases; 1%).
Efﬁ  cacy
Once the goals of risk factor modiﬁ  cation for patients 
with PAD have been met, the focus of PAD management 
shifts from general cardio-protection to treatment strategies 
speciﬁ  c for the clinical manifestations of PAD such as IC. 
There are consistent data supporting the efﬁ  cacy of cilo-
stazol for IC. In one the of most important studies included 
in the agent’s New Drug Application, 698 patients with 
moderate to severe IC were randomized to a standard dose 
of cilostazol 100 mg 2×/day, a standard dose of pentoxi-
fylline (400 mg 3×/day), or placebo (3×/day) for a period 
of 24 weeks. By the end of the study, patients included 
in the cilostazol group had shown a 54% improvement in 
maximal walking distance from the baseline compared with 
increases of 30% in the pentoxifylline group (p  0.05) 
and 34% in the placebo group (p  0.05) (Figure 2) 
(Dawson et al 2000). Earlier trials have demonstrated a 
dose-response relationship with cilostazol. In one study 
(Beebe et al 1999), IC patients who received cilostazol 
100 mg 2×/day for 24 weeks increased their maximal 
walking distance by 51% over the baseline, whereas those 
who received a 50 mg 2×/day dose showed an increase of 
only 38% compared to baseline values (p  0.001 for both 
doses versus placebo) (Figure 3). In a second trial, the net 
improvement in maximal walking distance over placebo 
was 21% with cilostazol 100 mg 2×/day compared to 7% 
for cilostazol 50 mg 2×/day. Notably, patients in both the 
50 mg and 100 mg cilostazol groups showed improvements 
in global measures of physical functioning compared 
to placebo-treated patients (p  0.05) (Strandness et al 
1998). Collectively, more than 2,700 IC patients were 
investigated in eight clinical trials with variable results, 
but there was a consistent trend toward improvement with 
cilostazol over placebo. Dawson et al (1998) and Money 
et al (1998) have shown a signiﬁ  cant improvement in 
maximal walking distance in those who received cilostazol 
100 mg 2×/day compared with those who received placebo. 
Recently, a meta-analysis from six phase III cilostazol 
trials (Regensteiner et al 2002) with study durations of 
12 to 24 weeks found a net beneﬁ  t of the drug in both the 
constant workload treadmill and graded treadmill tests. 
Among the 749 patients who had been evaluated with 
a constant workload treadmill test, cilostazol 100 mg 
2×/day was associated with a 76% improvement in maxi-
mal walking distance from the baseline compared with a 
20% improvement for placebo (p  0.0001). Similarly, 
895 patients evaluated with a graded treadmill test showed 
a 40% maximal walking distance improvement with cilo-
stazol 100 mg 2×/day compared with a 20% increase with 
placebo (p  0.05) (Figure 4). When data for both types 
of treadmill protocols were combined, cilostazol 100 mg 
2×/day demonstrated superiority over placebo in both 
maximal walking distance (p  0.05) and pain-free walk-
ing distance values (p  0.05). Furthermore, cilostazol 
demonstrated efﬁ  cacy on several pain and physical dimen-
sions on the Short Form-36 physical functioning scores 
and Walking Impairment Questionnaire, indicating that the 
drug’s beneﬁ  cial effects on exercise capacity are indeed 
*
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Figure 2 Mean percent change in maximal walking distance over time among 
intermittent claudication patients randomized to cilostazol 100 mg 2×/day 
(n = 227), pentoxifylline 400 mg 3×/day (n = 232), or placebo (n = 239) for 24 weeks. 
MWD = maximal walking distance. Reprinted from Dawson, DL, Cutler BS, Hiatt WR, 
et al 2000. A comparison of cilostazol and pentoxifylline for treating intermittent clau-
dication. Am J Med, 109:523–30. Copyright © 2000, with permission from Elsevier.Vascular Health and Risk Management 2008:4(6) 1201
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accompanied by meaningful improvements in QoL. The 
beneﬁ  cial effects of cilostazol were statistically superior 
to placebo as early as 4 weeks following treatment onset. 
However, the therapeutic effects of cilostazol were seen 
to improve progressively as study duration increased. In 
clinical practice, 12 to 24 weeks should be expected as a 
typical waiting period for improvement to occur.
In a randomized, placebo-controlled study, patients 
receiving either cilostazol 100 mg 2×/day, pentoxifylline 
400 mg 3×/day, or placebo were monitored for 24 weeks with 
cross-over to placebo after that period. When these patients 
were followed up for an additional 6 weeks, those in the 
cilostazol treatment group demonstrated a signiﬁ  cant loss of 
treatment beneﬁ  t after the change (p  0.05) (Cleanthis et al 
2005), whereas there was no signiﬁ  cant change following 
pentoxifylline therapy.
Interestingly, cilostazol has also been shown to provide 
long-term vessel patency after percutaneous transluminal 
angioplasty (PTA) in hemodialysis patients with PAD 
(Ishii et al 2008). In a recent Japanese study assessing 
lower extremity arterial patency rates 5 years after initial 
PTA, 193 hemodialysis patients with 372 consecutive 
lesions underwent successful PTA and were randomized to 
receive either cilostazol 100 mg 2×/day in conjunction with 
standard medical treatment (71 patients with 130 lesions) or 
standard medical therapy without cilostazol (122 patients 
with 242 lesions). After 5 years, the patency rate was 
52% in the cilostazol group and 33% in the control group 
(p  0.05). Moreover, in the Cilostazol for Restenosis 
Trial (Douglas et al 2005), 750 patients with successful 
coronary bare metal stent implantation were randomized 
to receive either cilostazol 100 mg 2×/day or placebo for 
6 months in additional to aspirin and clopidogrel 75 mg 
daily. At 6 months, the cilostazol group had a 36% rela-
tive risk reduction in the restenosis rate compared with 
those who received placebo, as determined by quantita-
tive coronary angiography. Furthermore, in the Cilostazol 
for Diabetic Patients in Drug-Eluting Stent Trial (Ahn 
et al 2008), 280 patients successfully underwent coronary 
stenting and were randomized to receive either aspirin 
and cilostazol or aspirin and clopidogrel. After a mean 
follow-up of 7.1 months, 237 patients underwent repeat 
coronary angiography; those randomized to receive aspi-
rin and cilostazol had a 50% decrease in the incidence of 
restenosis compared to those who received aspirin and 
clopidogrel. The trial concluded that combination therapy 
with aspirin and cilostazol for the prevention of restenosis 
is comparable and may even be superior to that of aspirin 
and clopidogrel in diabetic patients who undergo drug-
eluting stent implantation.
Supervised exercise rehabilitation is an effective and 
safe intervention that has been demonstrated to improve the 
walking distance of patients with IC. Multiple controlled 
trials have demonstrated that both walking distance until 
the onset of claudication and absolute claudication distance 
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Figure 3 Mean percent change in maximal walking distance (MWD) among intermittent 
claudication patients receiving cilostazol 100 mg 2×/day (n = 140), cilostazol 50 mg 2×/day 
(n = 139), or placebo (n = 140) for 24 weeks. Reprinted from Beebe, HG, Dawson DL, 
Cutler BS, et al 1999.   A new pharmacological treatment for intermittent claudication: 
results of a randomized, multicenter trial.  Arch Intern Med, 159:2041–50. Copyright © 
1999 with permission from American Medical Association.
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Figure 4 Mean absolute change in maximal walking distance (MWD), as measured by 
graded or constant-load protocols, among intermittent claudication patients receiv-
ing cilostazol 100 mg 2×/day, cilostazol 50 mg 2×/day, or placebo in six randomized 
controlled trials. Reprinted from Regensteiner JG, Ware JE Jr, McCarthy WJ, et al 2002. 
Effect of cilostazol on treadmill walking, community-based walking ability, and health-
related quality of life in patients with intermittent claudication due to peripheral arterial 
disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc, 50:1939–46. 
Copyright © 2002 with permission from Blackwell Publishing.Vascular Health and Risk Management 2008:4(6) 1202
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improve in patients who receive supervised exercise 
rehabilitation. One meta-analysis of 21 studies found that 
patients who were treated with supervised exercise reha-
bilitation had a 180% increase in distance walked until 
the onset of claudication compared with a 40% increase in 
control group individuals. Similarly, the absolute distance 
walked increased by 130% in patients who received super-
vised exercise rehabilitation compared with a 30% increase 
among those who did not (Gardner and Poehlman 1995). 
Another meta-analysis of 10 randomized trials comprising 
250 patients with IC found that initial maximal walking 
time increased by approximately 150% in patients treated 
with exercise rehabilitation compared with control group 
individuals (Leng et al 2000). Overall, supervised exercise 
therapy has been shown to be very effective in improving 
maximal treadmill walking distance (Milani and Lavie 
2007) (Figure 5).
Conclusions
In summary, cilostazol remains the only drug thus far 
proven to demonstrate consistent beneﬁ  ts in clinical trials 
in patients with IC. In addition to limb-speciﬁ  c outcomes, 
cilostazol has also been shown to provide pleotropic effects; 
these may provide additional clinical beneﬁ  ts, but clinical 
trials are needed to validate such effects. Finally, studies 
are also needed to compare the effects of cilostazol and 
supervised exercise training in patients with IC to either 
therapy by itself.
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